ライフサイエンスコーパス: geldanamycin

1 demethoxy-17-[[2-(dimethylamino)ethyl]amino]-geldanamycin.

2 ted and transfected cells in the presence of geldanamycin.

3 e, and 296 with negative correlations, e.g., geldanamycin.

4 ffect of the pharmacological Hsp90 inhibitor geldanamycin.

5 treatment of cells with the Hsp90 inhibitor geldanamycin.

6 early after stress or following exposure to geldanamycin.

7 astuzumab (Herceptin) or the Hsp90 inhibitor geldanamycin.

8 BCB1 substrates and with Baker's antifol and geldanamycin.

9 the HSP90 inhibitor 17-allylamino-demethoxy geldanamycin.

10 non-natural o-quino-GA product 55 10:1 over geldanamycin.

11 in COS-1 cells and subsequent treatment with geldanamycin.

12 superoxide dismutase inhibited the effect of geldanamycin.

13 otecting cka2-13 mutants on media containing geldanamycin.

14 he heat shock protein-90 chaperone inhibitor geldanamycin.

15 bition of the molecular chaperone Hsp90 with geldanamycin.

16 bits cell elongation in response to heat and geldanamycin.

17 TPase activity is competitively inhibited by geldanamycin.

18 sts after treatment with the Hsp90 inhibitor geldanamycin.

19 ng of hsp90alpha to 17-allyl-amino-demethoxy geldanamycin.

20 exquisite sensitivity to the HSP90 inhibitor geldanamycin.

21 The hsp90 inhibitor 17-allyl-amino-demethoxy geldanamycin (17-AAG) also induced polyubiquitylation an

22 Treatment with 17-allylamino-demothoxy geldanamycin (17-AAG) also inhibits ATP binding and chap

23 protein 90 inhibitor 17-allylamino-demethoxy geldanamycin (17-AAG) attenuated the levels of FLT-3 by

24 DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradati

25 17-Allylamino-demethoxy geldanamycin (17-AAG) inhibits the chaperone association

26 17-allylamino-demethoxy geldanamycin (17-AAG) inhibits the chaperone function of

27 hibitors, such as 17-allylamino-17-demethoxy-geldanamycin (17-AAG), constitute promising novel therap

28 HSP90 inhibitor, 17-allylamino-18-demethoxy-geldanamycin (17-AAG), in an imatinib-sensitive GIST cel

29 anamycin, such as 17-allylamino-17-demethoxy-geldanamycin (17-AAG), were the first HSP90 ATPase inhib

30 inhibitors, such as 17-allyl-amino-demethoxy-geldanamycin (17-AAG), whereas normal lymphocytes or ZAP

31 fect was additive with that of 17-allylamino-geldanamycin (17-AAG).

32 vities relative to 17-allyamino-17-demethoxy-geldanamycin (17-AAG).

33 A derivative of the antibiotic geldanamycin, 17-allylamino-17-demethoxygeldanamycin (17

34 he potential of 17-N-allylamino-17-demethoxy geldanamycin (17AAG), a geldanamycin derivative, to sens

35 ide (LY294002), 17-N-allylamino-17-demethoxy geldanamycin (17AAG), and (2E)-N-hydroxy-3-[4-[[(2-hydro

36 tely 70-85% by the selective HSP90 inhibitor geldanamycin (2 muM, 20 min).

37 mino-17-demethoxygeldanamycin (17-AAG, 4), a geldanamycin (3) derivative currently under evaluation f

38 measure affinity of [3H-allyl]17-allylamino geldanamycin ([3H]AAG) for the ATP binding site of the N

39 The Hsp90 inhibitor geldanamycin (50 nM, 100 nM, or 500 nM) was used to asse

40 ylmaleimide I, a selective PKC inhibitor, or geldanamycin, a benzoquinone ansamycin, which destabiliz

41 on with reticulocyte lysate was inhibited by geldanamycin, a drug that blocks the chaperone activity

42 beta)-bound Ack1 and treatment of cells with geldanamycin, a Hsp90 inhibitor, inhibited Ack1 kinase a

43 Geldanamycin, a HSP90alpha inhibitor, dissociated AKR1B1

44 d is increased by the chaperone-binding drug geldanamycin, a potent stimulator of ErbB2 ubiquitinatio

45 heat shock protein 90 (hsp90) function with geldanamycin abrogated BCR-induced cyclin D2 expression

46 y small interference RNA treatment inhibited geldanamycin-activated ubiquitination and proteolytic de

47 Geldanamycin, ADP, ATP, and radicicol-all known to bind

48 Geldanamycin affected the transcriptome of airway cells

49 Geldanamycin almost abolished this movement for P2X1 rec

50 Geldanamycin also binds to GRP94, the HSP90 paralog loca

51 Geldanamycin also inhibited native P2X1 receptor-mediate

52 Geldanamycin also reverted established goblet cell metap

53 position to prepare new analogues such as 17-geldanamycin amides, carbamates, and ureas and 17-arylge

54 The combination of bortezomib and geldanamycin (an hsp90 inhibitor) leads to greater apopt

55 Upon treatment of MCF-7 cells with geldanamycin, an ansamycin antibiotic that inhibits Hsp9

56 ng when diverted to the lysosomal pathway by geldanamycin, an effect partly due to proteolytic degrad

57 Treatment of cells with geldanamycin, an Hsp90 inhibitor, enhanced ubiquitinatio

58 Geldanamycin, an HSP90 inhibitor, markedly inhibited IL-

59 ed after PDTC treatment or after exposure to geldanamycin, an Hsp90 inhibitor.

60 LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, induced degra

61 ecipitation and was effectively disrupted by geldanamycin, an Hsp90-specific inhibitor.

62 Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases includin

63 Treatment of cells with geldanamycin, an inhibitor of heat shock protein 90 (Hsp

64 nse profile connectivity approach identified geldanamycin, an inhibitor of heat shock protein 90 (HSP

65 xpressing recombinant GC-A were treated with geldanamycin, an inhibitor of hsp90 function, the ANP-st

66 Geldanamycin, an inhibitor of Hsp90, results in decrease

67 by treatment with boiling, proteinase K, and geldanamycin, an inhibitor of hsps, suggesting that hsps

68 Treatment with geldanamycin, an inhibitor of the chaperone heat shock p

69 This process can be driven by geldanamycin, an irreversible blocker of Hsp90.

70 cytosolic Src-cdc37-HSP90 complex with 17 nM geldanamycin, an optimum concentration for affecting thi

71 Inhibition of Hsp90 function using the geldanamycin analog 17-AAG induces the ubiquitination an

72 ngs for use of hsp90 inhibitors, such as the geldanamycin analog 17-AAG.

73 IPI-504 was compared with that of 17-AAG, a geldanamycin analog currently in clinical trials.

74 Structure and potency analysis classified 18 geldanamycin analogs into two subgroups, "17-O/H" (C-17

75 In structure-activity studies of geldanamycin analogs, 17-AAG and 17-DMAG were most selec

76 ignificant correlation was observed with the geldanamycin analogue 17-allylamino, 17-demethoxygeldana

77 In addition, we confirmed the selectivity of geldanamycin analogues for Hsp90 derived from tumor cell

78 promoting its proteasomal degradation, e.g., geldanamycin analogues, have also been identified.

79 al carcinoma cell lines (HeLa and SiHa) with geldanamycin and 17-AAG resulted in cytotoxicity and, wh

80 onjugate, bound to Hsp90 in a similar way as geldanamycin and 17-AG.

81 ivity including the benzoquinone ansamycins, geldanamycin and 17-allylamino-17-demethoxygeldanamycin,

82 and E255K) were examined for sensitivity to geldanamycin and 17-allylaminogeldanamycin (17-AAG).

83 other ErbB1 ligands or the ErbB2 inhibitors geldanamycin and AG825.

84 C7A11 in HepG2 cells, which are sensitive to geldanamycin and express low SLC7A11, confers resistance

85 herefore, we hypothesized that the ansamycin geldanamycin and its 17-allylamino-17-demethoxy analog (

86 Geldanamycin and its derivative 17AAG [17-(Allylamino)-1

87 The benzoquinone ansamycin geldanamycin and its derivatives are inhibitors of heat

88 henyl- and 19-methyl-substituted versions of geldanamycin and its derivatives, 17-allylamino-17-demet

89 Geldanamycin and its less toxic analogue, 17- (allylamin

90 -down assays and the Hsp90 inhibitory agents geldanamycin and molybdate, Cdk2 is shown to be a genuin

91 We also report that hsp90 inhibitors geldanamycin and novobiocin inhibit recombinant telomera

92 Our experiments confirmed that geldanamycin and other HSP90 inhibitors prevented IL-13-

93 The antibiotics geldanamycin and radicicol act as highly selective inhib

94 Geldanamycin and radicicol are structurally different ma

95 Treatment of human B cells with geldanamycin and radicicol did not alter cellular MHC cl

96 The known HSP90 inhibitors geldanamycin and radicicol gave IC(50) values of 4.8 and

97 Geldanamycin and radicicol had nanomolar potency in vitr

98 S has identified the bioactive conformers of geldanamycin and radicicol in CDCl3 solution with popula

99 Both geldanamycin and radicicol, two structurally different H

100 of radamide, an open chain amide chimera of geldanamycin and radicicol.

101 tionale has been that inhibition of hsp90 by geldanamycin and related compounds activates heat shock

102 The HSP90-specific inhibitor geldanamycin and RNAi-mediated depletion of cytoplasmic

103 In A549 cells, which are resistant to geldanamycin and strongly express SLC7A11, inhibition of

104 ries of macrocylic chimeras of radicicol and geldanamycin and the corresponding seco-agents have been

105 Both geldanamycin and the HSP90-specific inhibitor, 514, led

106 fluential role of the benzoquinone ansamycin geldanamycin and the resorcylic acid macrolactone radici

107 molecular chaperones, including tunicamycin, geldanamycin, and lactacystin.

108 ast increases Hsp90 binding to its inhibitor geldanamycin, and pharmacologic inhibition/silencing of

109 re sensitive to the Hsp90-specific inhibitor geldanamycin, and this sensitivity was suppressed by ove

110 When these geldanamycin- and 17-AAG-resistant cells were transfecte

111 samycins such as rifamycin, ansamitocin, and geldanamycin are an important class of polyketide natura

112 Two analogues of the Hsp90 inhibitor geldanamycin are currently in clinical trials.

113 ted that the natural products, radicicol and geldanamycin, are potent inhibitors of the Hsp90 N-termi

114 tion on hsp90, cautioning against the use of geldanamycin as a specific inhibitor of hsp90 in redox-a

115 n light of these findings, the studies using geldanamycin as an inhibitor of Hsp90 should be interpre

116 y coupling a galactose-amine derivative with geldanamycin at the C-17 position.

117 tion of the Src-cdc37-HSP90 complex by 17 nM geldanamycin at the cellular level, we investigated its

118 The results showed that geldanamycin at this concentration could also abolish th

119 p90.PAR-1 complex by the Hsp90-specific drug geldanamycin attenuated thrombin-mediated astrocyte shap

120 The three geldanamycin-based and seven purine-scaffold Hsp90 inhib

121 ort of a functional reliance, treatment with geldanamycin-based HSP90 inhibitors resulted in rapid de

122 ted cells secreting the GRP94 NH(2)-terminal geldanamycin-binding domain (NTD), a region lacking cano

123 harged domains of Hsp90, including the Hsp90 geldanamycin-binding domain.

124 talyzed by the post-PKS tailoring enzymes in geldanamycin biosynthesis.

125 ay that measures the binding of biotinylated geldanamycin (biotin-GM) to the His-tagged human Hsp90 N

126 Inhibition of Hsp90 with 100 nM or 500 nM geldanamycin blocked IGF-1-induced cell proliferation, A

127 However, we show here that geldanamycin blocks the development of aggregates of the

128 its interaction with GRP94, not HSP90, since geldanamycin but not 514 led to up-regulation of BiP.

129 orrelation with growth inhibitory potency of geldanamycin but not with its analog 17-(allylamino)-17-

130 fers resistance selectively to 17-O/H (e.g., geldanamycin) but not to 17-N (e.g., 17-AAG) analogs par

131 r glutathione levels and enhanced potency of geldanamycin, but did not affect L-alanosine.

132 d express low SLC7A11, confers resistance to geldanamycin, but not to 17-AAG.

133 ake of L-alanosine but confers resistance to geldanamycin by supplying cystine for glutathione mainte

134 f the inhibition of Hsp90 and indicates that geldanamycin cannot be used as a specific inhibitor of H

135 ment of K562 cells with the Hsp90 inhibitor, geldanamycin, caused a 75% reduction in Cdk2 levels and

136 At a concentration of 20 microm, geldanamycin causes a 3-fold increase in NADPH oxidation

137 fe was markedly decreased in the presence of geldanamycin compared with that in control.

138 s revealed that aurin displays activity as a geldanamycin-competitive Hsp90alpha-antagonist, a findin

139 lem, we synthesized a series of carbohydrate-geldanamycin conjugates for enzyme-specific activation t

140 Geldanamycin contains a quinone group, which may partici

141 Inhibition by geldanamycin could be overcome by allowing telomerase to

142 Radicicol and geldanamycin could both maintain chaperone induction for

143 Geldanamycin decreased the bioavailable nitric oxide gen

144 at 17-allylamino-17-demethoxygeldanamycin, a geldanamycin delivative, radiosensitized HT-29 cells at

145 ylamino-17-demethoxygeldanamycin (17-AAG), a geldanamycin derivative (IC50: 16 muM).

146 ypothesis, 2 different Hsp90 inhibitors, the geldanamycin derivative 17-DMAG and the nontoxic peptide

147 ylamino-17-demethoxy geldanamycin (17AAG), a geldanamycin derivative, to sensitize tumor cells to ion

148 s were encountered for three of the five new geldanamycin derivatives, which matched well with a comp

149 Geldanamycin did not induce goblet cell death, nor did i

150 In contrast, geldanamycin did not inhibit the activity of preformed F

151 Furthermore, geldanamycin did not promote premature protein A degrada

152 In the absence of cells, geldanamycin directly oxidized ascorbate, consumed oxyge

153 with the known propensity of other quinones, geldanamycin directly redox cycles with nNOS by a proces

154 In contrast to the Hsp90 inhibitor geldanamycin, Disruptin inhibits cancer cell growth by a

155 Addition of geldanamycin does not result in hyphal extensions at 30

156 By contrast, geldanamycin down-regulates surface ErbB2 through improv

157 Geldanamycin effectively promotes the degradation of CRA

158 Geldanamycin effects were attributed to a selective depl

159 The HSP90 inhibitor geldanamycin enhances the degradation of IKKalpha and bl

160 one ansamycin (BQA) Hsp90 inhibitors such as geldanamycin (GA) and 17-(allylamino)-17-demethoxygeldan

161 atus were incubated with the Hsp90 inhibitor geldanamycin (GA) and analysed by western blotting for t

162 Geldanamycin (GA) and its analogues 17-AAG [17-(allylami

163 Geldanamycin (GA) and its analogues have been reported t

164 itumor activity of Hsp90 inhibitors, such as geldanamycin (GA) and its derivative 17-allylamino-demet

165 The ansamycins, geldanamycin (GA) and its derivative, 17-allylaminogelda

166 ociation is sensitive to the Hsp90 inhibitor geldanamycin (GA) and that GA inhibits the ability of al

167 as abolished by the specific HSP90 inhibitor geldanamycin (GA) at both calcium concentrations.

168 Geldanamycin (GA) disrupted HSP90-eNOS binding, reduced

169 Several chaperone-binding drugs based on geldanamycin (GA) have been synthesized, and one of them

170 ly that pharmacologic inhibition of Hsp90 by geldanamycin (GA) impairs HIF transcription and promotes

171 Treatment with geldanamycin (GA) increased the activity of PPARalpha an

172 p90 inhibitory ansamycin antibiotics such as geldanamycin (GA) induce rapid ubiquitinylation and down

173 The ansamycin antibiotic geldanamycin (GA) induces the intracellular degradation

174 Geldanamycin (GA) is a potent anticancer antibiotic that

175 Geldanamycin (GA) is an antibiotic produced by Actinomyc

176 ur results show that treatment of cells with geldanamycin (GA) leads to degradation of DAPK, and this

177 ndings indicate that treatment of cells with geldanamycin (GA) or MG-132 (an inhibitor of the 26S pro

178 Here we report that conjugating geldanamycin (GA) to the anti-HER2 mAb Herceptin improve

179 ther hsp90 is required for apoB degradation, geldanamycin (GA) was added during the degradation assay

180 The effects of geldanamycin (GA), 17-(3-aminopropylamino)-17-demethoxyg

181 Geldanamycin (GA), a specific Hsp90 inhibitor, disrupts

182 ot experiments, as well as by treatment with geldanamycin (GA), a specific Hsp90 inhibitor.

183 d upon incubation of murine macrophages with geldanamycin (GA), a specific inhibitor of the Hsp90 fam

184 an ATP-dependent manner that was blocked by geldanamycin (GA), an established Hsp90 inhibitor.

185 Geldanamycin (GA), an Hsp90 antagonist, promoted efficie

186 In monocytic cells, geldanamycin (GA), an Hsp90 inhibitor, effectively promo

187 effect as well as the molecular mechanism of geldanamycin (GA), an inhibitor of Hsp90, on 1-methyl-4-

188 ural products and their derivatives, such as geldanamycin (GA), are well-known inhibitors of the esse

189 The total synthesis of (+)-geldanamycin (GA), following a linear route, has been co

190 HSP90 inhibitors, such as geldanamycin (GA), have been developed to target the rec

191 Geldanamycin (GA), heat shock, and osmotic shock treatme

192 of heat-shock protein 90 (HSP90) inhibitor, geldanamycin (GA), on IR-induced G(2) arrest in human co

193 ate that treatment with ansamycin antibiotic geldanamycin (GA), or its less toxic analogue 17-allylam

194 o 2,3,7,8-tetrachlorodibezo-p-dioxin (TCDD), geldanamycin (GA), or the protease inhibitor carbobenzox

195 rs) induced by the HSP90 chaperone inhibitor geldanamycin (GA), whereas its downregulation and lysoso

196 Geldanamycin (GA), which inhibits hsp90 and increases ox

197 ing to Hsp90 by the Hsp90-specific inhibitor geldanamycin (GA).

198 Geldanamycins (GA) are antitumor drugs that bind and inh

199 Geldanamycin (GD) is a benzoquinone ansamycin that inhib

200 rticular, the quinone-containing antibiotics geldanamycin (GDA) and herbimycin A inhibit Hsp90 functi

201 h several derivatives of the natural product geldanamycin (GdA) now in clinical trials.

202 ian GRP94, bound to the pan-Hsp90 inhibitors geldanamycin (Gdm) and radamide.

203 In an effort to identify analogues of geldanamycin (GDM) with properties superior to those of

204 olyketides (mccrearamycins A-D), and six new geldanamycins (Gdms B-G, including new linear and mycoth

205 These findings demonstrate that geldanamycin generates O(2)(*)(-), which scavenges nitri

206 The natural products geldanamycin (GM) and radicicol (RD) are known inhibitor

207 The K(d) values of the N-terminus ligands geldanamycin (GM, 90+/-50 nM), 17-allylamino-17-demethox

208 ibition of Hsp90 also decreases IKr, whereas geldanamycin had no effect on IKs or heterologously expr

209 The ansamycin antibiotic geldanamycin has frequently been used as an inhibitor of

210 n of these ligands, hybrids of radicicol and geldanamycin have been designed.

211 whereas the classical Hsp90 inhibitors (e.g. geldanamycin) have no effect.

212 0 inhibitor 17-N,N-dimethyl ethylene diamine-geldanamycin in vivo.

213 Exposure of EGFR-mutant cell lines to geldanamycin induced marked depletion of phospho-Akt and

214 , and NCI-H1975, were also more sensitive to geldanamycin-induced degradation compared with the prote

215 The geldanamycin-induced degradation of HIF-1alpha was rever

216 of these residues to arginine suppressed the geldanamycin-induced degradation of KDM4B, suggesting th

217 lying that Cbl does not play a major role in geldanamycin-induced ErbB2 down-regulation.

218 at flavin-containing enzymes are involved in geldanamycin-induced O(2)(*)(-) generation.

219 e show that the prototypical Hsp90 inhibitor geldanamycin induces Akt and Erk activation that is inde

220 We conclude that geldanamycin induces reduction of HIF-1alpha levels and

221 An Hsp90 ATPase inhibitor, geldanamycin, inhibits luciferase reactivation demonstra

222 The HSP90-binding drug geldanamycin interferes with this activity and promotes

223 In an effort to convert geldanamycin into a druglike compound with better pharma

224 Geldanamycin is additionally known to inhibit hsp90-depe

225 Geldanamycin is an ansamycin benzoquinone, and we show h

226 ubstituent in that the the methoxy moiety of geldanamycin is replaced by an amino group.

227 Inactivation of Hsp90 by geldanamycin led to decreased SGK-1 phosphorylation inde

228 Compared with 17-AAG, geldanamycin led to significantly more intracellular rea

229 In contrast, HSP90 inhibition by geldanamycin markedly enhances TRAIL-induced DNA-PK and

230 FL overexpression prevented geldanamycin-mediated loss of total and phospho-Akt and

231 red that inhibition of hsp90 by radicicol or geldanamycin nearly prevents the heme-mediated activatio

232 Furthermore, the Hsp90 inhibitor geldanamycin negated the effects of phosphatase inhibito

233 The suppressive effect of geldanamycin on protein A synthesis was not attenuated b

234 Treatment with geldanamycin or glutathione, overexpression of Ssa3 (Hsp

235 ction of Hsp70 through treatment with either geldanamycin or heat shock factor 1 leads to a decrease

236 Geldanamycin or herbimycin A, tyrosine kinase inhibitors

237 HSP90 inhibition by the antibiotic geldanamycin or its derivative 17-allylamino-17-demethox

238 tivation of the stress protein response with geldanamycin or pyrrolidine dithiocarbamate.

239 Inactivation of HSP90 function using geldanamycin or radicicol inhibited MHC class II present

240 a S2 cells with the Hsp90-specific inhibitor geldanamycin or radicicol potently suppressed the produc

241 ed by 40-45% following HSP90 inhibition with geldanamycin or radicicol.

242 Furthermore, Hsp90 inhibition with either geldanamycin or RNAi-mediated chaperone downregulation s

243 ecific mechanism, and inhibition of Hsp90 by geldanamycin or small interfering RNA-mediated lowering

244 er the HSP (heat shock protein) 90 inhibitor geldanamycin or the ErbB inhibitor ZD1839 in SKBR3 cells

245 ntexts, such as when Hsp90 is inhibited with geldanamycin or when CDC37 is mutated.

246 t is linked to an inhibitor of either Hsp90 (geldanamycin) or Abl kinase (imatinib).

247 d to thapsigargin, A23187, brefeldin A, DTT, geldanamycin, or bortezomib manifested reduced activatio

248 53S occurred following exposure to 50 nmol/L geldanamycin over 24 hours, whereas partial diminution o

249 Ansamycin antibiotics, such as geldanamycin, potently inhibit heat shock protein 90 (Hs

250 Inhibition of hsp90-p53 interaction by geldanamycin prevented p53 accumulation partially in ATM

251 The specific Hsp90 inhibitor geldanamycin prevents maturation and increases proteasom

252 ta-galactosidase) to specifically activate a geldanamycin prodrug (17-AG-C2-Gal) against colon cancer

253 The geldanamycin prodrug 17-AG-C2-Gal was synthesized by cou

254 The amide synthase of the geldanamycin producer, Streptomyces hygroscopicus, shows

255 d the molecular mechanisms by which the drug geldanamycin protects neurons against alpha-synuclein to

256 Geldanamycin, PS-341, and TRAIL triple combination may b

257 ngle and combined antitumor drugs, including geldanamycin, PS-341, Trichostatin A, and doxorubicine.

258 er, and metabolic labeling demonstrated that geldanamycin rapidly accelerated the degradation of newl

259 We show that geldanamycin rapidly disrupts Src association with Hsp90

260 harmacologic inhibition of Hsp90 function by geldanamycin reduces, whereas overexpression of Hsp90 in

261 cell line selected for stable resistance to geldanamycin relative to parent cells showed increased H

262 Inhibition of HSP90 activity with geldanamycin restored Cbl function as indicated by recep

263 The treatment of endothelial cells with geldanamycin resulted in a dramatic increase in O(2)(*)(

264 in misfolding by puromycin, thapsigargin, or geldanamycin resulted in inflammasome activation that wa

265 Pharmacological inhibition of Hsp90 with geldanamycin resulted in ubiquitin-dependent proteasomal

266 Treatment with the Hsp90-specific inhibitor geldanamycin selectively reduced FHV RNA polymerase synt

267 tracellular N and C termini were involved in geldanamycin sensitivity.

268 Our studies show that geldanamycin sensitizes the stress response within norma

269 The hsp90 inhibitor, geldanamycin, similarly blocked transcriptional activity

270 Derivatives of the natural product geldanamycin, such as 17-allylamino-17-demethoxy-geldana

271 action in endothelial cells was prevented by geldanamycin, suggesting heat shock protein 90 as a bind

272 Interestingly, geldanamycin-targeted phosphorylation sites were not lim

273 13 mRNA was blocked by all concentrations of geldanamycin tested.

274 Treatment of cells with geldanamycin to disrupt the Hsp90 complex led to proteas

275 Further, the previously reported ability of geldanamycin to stimulate ER stress-dependent transcript

276 degradation of the 185-kDa native ErbB-2 in geldanamycin-treated cells but does significantly preven

277 f SCF(ZTL), TOC1 and PRR5, are stabilized in geldanamycin-treated seedlings, whereas the levels of cl

278 Our finding that geldanamycin treatment does not affect the cellular leve

279 Interestingly, geldanamycin treatment of HL60 cells decreased the expre

280 tween HIF-1alpha mRNA levels before or after geldanamycin treatment was found.

281 Geldanamycin treatment, which disrupts the HSP90-FKBP52

282 Geldanamycin treatment, which specifically inhibits Hsp9

283 of MLK3 and JNK in MCF-7 cells is blocked by geldanamycin treatment.

284 on at the same residues as those affected by geldanamycin treatment.

285 t has been reported that the hsp90 inhibitor geldanamycin uncouples endothelial NOS activity and incr

286 Further, geldanamycin uncouples neuronal toxicity from Lewy body

287 nd efficacy in human tumor xenograft models, geldanamycin was derivatized on the 17-position to prepa

288 When geldanamycin was exposed to the flavin-containing enzyme

289 s suggested that GRK2 degradation induced by geldanamycin was predominantly through the proteasome pa

290 the hsp90-specific inhibitors radicicol and geldanamycin, we show that hsp90 is required for the con

291 The effects of Hsp90 inhibition with geldanamycin were concentration dependent.

292 ter only 4 hours of exposure to 1 micromol/L geldanamycin, whereas diminution of wild-type EGFR was l

293 anes, and by Hsp90 inhibitors, radicicol and geldanamycin, which are known to inhibit Rab3a dissociat

294 Importantly, the hybrids composed of Az and geldanamycin, which have high inhibitory activities towa

295 ntrast to the effects of the Hsp90 inhibitor geldanamycin, which induces eNOS ubiquitylation and its

296 Geldanamycin, which inhibits Src kinase, also abrogated

297 his further resulted in increased potency of geldanamycin, with no effect on 17-AAG.

298 beta, ERBB, or EHF, which would predict that geldanamycin would also revert IL-17-induced goblet cell

299 ess response, via exposure to either heat or geldanamycin, would attenuate the release of airspace ni

300 osine and glutathione-mediated resistance to geldanamycin, yielding a potential target for increasing